Loading...
Neutralizing antibodies have been shown to protect against HIV infection in laboratory and animal studies, but few data are available about their effects in humans. With partial industry support, investigators conducted a nonrandomized, unblinded, proof-of-principle study to evaluate the potential of three neutralizing antibodies (2G12, 2F5, and 4E10) to suppress viral load following antiretroviral treatment interruption. Thirteen doses of the three antibodies were administered over 11 weeks to eight individuals with chronic HIV infection and six with acute infection. Subjects were followed for 24 weeks.
Two of the eight chronically infected individuals showed evidence of a delay in viral rebound. In both cases, the peak in viral load was de…